Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA PMA/PDP sign-off authority

This article was originally published in The Gray Sheet

Executive Summary

Agency amends in a May 18 Federal Register notice the regulations for delegation of authority to allow division directors within the Office of Device Evaluation in FDA's Center for Devices and Radiological Health to approve, disapprove or withdraw approval of premarket approval applications and product development protocols. "As a result of reengineering initiatives within CDRH...this delegation will improve the efficiency of operations for these programs," the notice explains

Latest Headlines
See All
UsernamePublicRestriction

Register

MT010082

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel